Psylutions Leads Colorado’s Regulated Psychedelic Market with Healing Center Collaborations

Colorado's first licensed psilocybin cultivator and manufacturer now provideshigh-quality, scientifically backed products to more than half of the state'slicensed healing centers Psylutions, Colorado's first licensed psilocybin cultivator and manufacturer, has announced partnerships with more than half of Colorado's licensed healing centers, marking a significant milestone in the development of the nation's first regulated psilocybin marketplace. […]

Holiday Beef Recipes That Make the Season Simple

The Beef. It's What's For Dinner. brand serves up recipes to keep festive cooking flavorful and convenient for the holidays. The holiday season often means a full calendar and even fuller grocery lists, making meal planning more important that ever. Whether you're planning a full menu for the celebration of the season or repurposing leftovers,

Insilico Medicine and TaiGen Achieves License Agreement to Develop and Commercialize AI-driven PHD Inhibitor for Anemia of Chronic Kidney Disease (CKD)

— Insilico Medicine has licensed TaiGen Biotechnology exclusive rights in the Greater China area to develop, commercialize, and sub-license ISM4808, an AI-driven potential best-in-class oral PHD inhibitor with IND clearance granted in 2023. — The partnership combinesInsilico's generative AI discovery platform with TaiGen's regional clinical and commercial expertise to accelerate the development of ISM4808 for

Lotus Tech Debuts its First PHEV, Advancing into Wider Markets

Lotus Tech Debuts its First PHEV, Advancing into Wider Markets GlobeNewswire December 12, 2025 NEW YORK, Dec. 12, 2025 (GLOBE NEWSWIRE) — Lotus Technology Inc. (the “Company”) (Nasdaq: LOT) today provided an update on its new plug-in hybrid (PHEV) model. The model made its public debut on December 5, 2025 through inclusion in the Ministry

Option Care Health to Participate in the J.P. Morgan Healthcare Conference

Option Care Health to Participate in the J.P. Morgan Healthcare Conference GlobeNewswire December 12, 2025 BANNOCKBURN, Ill., Dec. 12, 2025 (GLOBE NEWSWIRE) — Option Care Health, Inc. (“Option Care Health”) (Nasdaq: OPCH), the nation's largest independent provider of home and alternate site infusion services, will participate in the 44th Annual J.P. Morgan Healthcare Conference, being

Novartis breaks ground on flagship manufacturing hub in North Carolina

Novartis breaks ground on flagship manufacturing hub in North Carolina GlobeNewswire December 12, 2025 FDA Commissioner Marty Makary, North Carolina Governor Josh Stein and Novartis leadership highlight importance of new hub to US patients and local economy Construction reflects company's commitment to ensure end-to-end manufacturing of all key medicines for US patients in the US

Stallion Uranium Announces Flow Through Financing

Stallion Uranium Announces Flow Through Financing GlobeNewswire December 12, 2025 NOT FOR DISTRIBUTION TO UNITED STATES NEWS WIRE SERVICES OR FOR DISSEMINATION IN THE UNITED STATES VANCOUVER, British Columbia, Dec. 12, 2025 (GLOBE NEWSWIRE) — Stallion Uranium Corp. (the “Company” or “Stallion“) (TSX-V: STUD; OTCQB: STLNF; FSE: B76) is pleased to announce that it is

Holiday Grief Intensifies as Americans Seek Practical Relief Methods

Holiday Grief Intensifies as Americans Seek Practical Relief Methods GlobeNewswire December 12, 2025 LOS ANGELES, Dec. 12, 2025 (GLOBE NEWSWIRE) — The first week of December marked National Grief Awareness Week, a time dedicated to recognizing the impact of grief and supporting those who have experienced loss. With the holiday season upon us, these emotions

BioCryst Announces FDA Approval of ORLADEYO(R) (berotralstat) Oral Pellets, First and Only Oral Prophylactic Treatment for Patients with HAE Aged 2 to <12 Years

BioCryst Announces FDA Approval of ORLADEYO(R) (berotralstat) Oral Pellets, First and Only Oral Prophylactic Treatment for Patients with HAE Aged 2 to <12 Years GlobeNewswire December 12, 2025 –ORLADEYO now first and only targeted oral prophylactic therapy for patients with HAE aged 2 and older– -Oral pellet formulation provides child-friendly method of administration- -Showed early

Revuforj(R) (revumenib) Named Best New Drug at the Scrip Awards 2025

Revuforj(R) (revumenib) Named Best New Drug at the Scrip Awards 2025 GlobeNewswire December 12, 2025 NEW YORK, Dec. 12, 2025 (GLOBE NEWSWIRE) — Syndax Pharmaceuticals (Nasdaq: SNDX), a commercial-stage biopharmaceutical company advancing innovative cancer therapies, today announced that Revuforj(R) (revumenib) was named Best New Drug at the Scrip Awards 2025, held by Citeline. The Best

Scroll to Top